Wegovy vs Foundayo: Full Comparison (2026)
How does Wegovy (Semaglutide) compare to Foundayo (Orforglipron)? We break down the weight loss data, pricing, side effects, and who each medication is best suited for.
Wegovy (Semaglutide, GLP-1 receptor agonist) and Foundayo (Orforglipron, Oral non-peptide GLP-1 receptor agonist) work through different mechanisms. Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction with 15-17% of body weight average weight loss at $1,349/mo. Foundayo is approved for chronic weight management with up to 12.4% of body weight (ATTAIN-1, top dose) average weight loss at $149/mo.
Side-by-Side Comparison
| Feature | Wegovy | Foundayo |
|---|---|---|
| Active Ingredient | Semaglutide | Orforglipron |
| Mechanism | GLP-1 receptor agonist | Oral non-peptide GLP-1 receptor agonist |
| FDA Approved For | Chronic weight management, Cardiovascular risk reduction | Chronic weight management |
| Doses | 0.25mg to 2.4mg (weekly injection), oral pill available | 0.8mg start, titrating every 4 weeks to 5.5mg, 9mg, or 17.2mg (once-daily pill) |
| Administration | Weekly subcutaneous injection or daily oral pill | Once-daily oral tablet — no food or water restrictions |
| Avg. Weight Loss | 15-17% of body weight | up to 12.4% of body weight (ATTAIN-1, top dose) |
| Monthly Price | $1,349 | $149 |
| Oral Available | Yes | Yes |
| Year Approved | 2021 | 2026 |
Prices reflect typical self-pay costs without insurance. Actual costs vary by pharmacy, location, and insurance plan. Last updated March 2026.
Which Produces More Weight Loss?
Based on clinical data, Wegovy produces more weight loss on average (15-17% of body weight) compared to Foundayo (up to 12.4% of body weight (ATTAIN-1, top dose)). Wegovy uses Semaglutide (GLP-1 receptor agonist), while Foundayo uses Orforglipron (Oral non-peptide GLP-1 receptor agonist), which may account for the difference.
FDA-approved specifically for chronic weight management. Higher dose of semaglutide than Ozempic. Oral version launched January 2026.
The first oral small-molecule GLP-1 approved for weight loss (FDA approved April 1, 2026). A once-daily pill taken with no food or water restrictions. Lower peak efficacy than injectable tirzepatide or semaglutide, but far cheaper cash-pay at $149/month and far more convenient — no needles.
Which Costs Less?
At list price, Foundayo is the more affordable option at $149/month compared to $1,349/month for Wegovy. However, actual out-of-pocket costs depend heavily on your insurance plan. Wegovy with insurance: $25-$200/month typical copay. Foundayo with insurance: $50/mo via Medicare Bridge; ~$25/mo with eligible commercial coverage.
Oral pill: $149/month at lowest dose (launched Jan 2026)
$149/month cash via LillyDirect (no insurance required)
Side Effects Comparison
Both Wegovy (GLP-1 receptor agonist) and Foundayo (Oral non-peptide GLP-1 receptor agonist) share similar gastrointestinal side effects, which are the most commonly reported:
- Nausea (most common for both medications)
- Diarrhea and vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Headache, fatigue, dizziness (less common)
Serious but rare side effects for both include pancreatitis, gallbladder problems, and kidney issues. Both carry warnings about medullary thyroid carcinoma risk based on animal studies. Always discuss your full medical history with your doctor before starting either medication.
Which Should You Choose?
The best choice depends on your diagnosis, insurance coverage, weight loss goals, and personal preferences. Here is our general guidance:
- -Your primary goal is weight loss (FDA-approved indication)
- -You prefer an oral option over injections
- -You prefer a daily dosing routine
- -Your primary goal is weight loss (FDA-approved indication)
- -You prefer an oral option over injections
- -Cost is a concern ($149/month at list price)
- -You prefer a daily dosing routine
Find the Best GLP-1 Provider for You
Compare verified telehealth programs that prescribe Wegovy, Foundayo, and other FDA-approved GLP-1 medications.
Frequently Asked Questions
Can I switch from Wegovy to Foundayo?
Switching between Wegovy and Foundayo is possible but requires medical supervision since they contain different active ingredients (Semaglutide vs Orforglipron). Your doctor will determine the appropriate starting dose and titration schedule for the new medication.
Which is better for weight loss: Wegovy or Foundayo?
Clinical data suggests Wegovy produces more weight loss on average (15-17% of body weight) compared to Foundayo (up to 12.4% of body weight (ATTAIN-1, top dose)). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.
Is Wegovy cheaper than Foundayo?
At list price, Foundayo ($149/month) is less expensive than Wegovy ($1,349/month). With insurance, costs vary significantly. Wegovy: $25-$200/month typical copay. Foundayo: $50/mo via Medicare Bridge; ~$25/mo with eligible commercial coverage.
Do Wegovy and Foundayo have the same side effects?
Both medications share similar gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) as these are common to GLP-1 receptor agonists. However, since they contain different active ingredients, there may be differences in frequency and severity. Discuss your medical history with your doctor to determine which has a better safety profile for you.
Does insurance cover Wegovy and Foundayo?
Coverage varies by plan. Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction — insurance coverage is typically better for on-label use. Foundayo is FDA-approved for chronic weight management. Check with your specific insurance plan and ask your doctor about prior authorization requirements.